Not OP obv, but based on the sample size and NIH reference I found the paper and the following down in the results section:
In the meta-analysis incorporating the time-varying estimates from all 3 cohorts, daily MV use, compared with nonuse, was associated with a 4% higher risk of all-cause mortality in FP1 (HR, 1.04; 95% CI, 1.02-1.07) but not in FP2 (HR, 0.98; 95% CI, 0.93-1.04) (Figure 2).
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820369
Yup exactly I was quoting that part to point out that it was only found in the results of the meta analysis of all the studies in follow up period 1 but I wasnt very specific about that, i.e. I was not intending to validate the title's claim.